DK3391902T3 - Plasminogen til anvendelse i behandlingen af diabetisk angiokardiopati - Google Patents
Plasminogen til anvendelse i behandlingen af diabetisk angiokardiopati Download PDFInfo
- Publication number
- DK3391902T3 DK3391902T3 DK16874928.1T DK16874928T DK3391902T3 DK 3391902 T3 DK3391902 T3 DK 3391902T3 DK 16874928 T DK16874928 T DK 16874928T DK 3391902 T3 DK3391902 T3 DK 3391902T3
- Authority
- DK
- Denmark
- Prior art keywords
- angiocardiopathy
- plasminogen
- diabetic
- treatment
- diabetic angiocardiopathy
- Prior art date
Links
- 102000013566 Plasminogen Human genes 0.000 title 1
- 108010051456 Plasminogen Proteins 0.000 title 1
- 206010012601 diabetes mellitus Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/484—Plasmin (3.4.21.7)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6456—Plasminogen activators
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2015097947 | 2015-12-18 | ||
| PCT/CN2016/110453 WO2017101871A1 (zh) | 2015-12-18 | 2016-12-16 | 一种预防和治疗心血管病的新方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DK3391902T3 true DK3391902T3 (da) | 2023-11-20 |
| DK3391902T5 DK3391902T5 (da) | 2024-09-23 |
Family
ID=59055774
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16874928.1T DK3391902T5 (da) | 2015-12-18 | 2016-12-16 | Plasminogen til anvendelse i behandlingen af diabetisk angiokardiopati |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US11338022B2 (da) |
| EP (1) | EP3391902B1 (da) |
| JP (2) | JP6783870B2 (da) |
| CN (1) | CN108778320A (da) |
| DK (1) | DK3391902T5 (da) |
| ES (1) | ES2961967T3 (da) |
| TW (1) | TWI624268B (da) |
| WO (1) | WO2017101871A1 (da) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3008466C (en) | 2015-12-18 | 2023-06-20 | Talengen International Limited | Method for preventing or treating radiation and chemical damage |
| JP6876066B2 (ja) | 2015-12-18 | 2021-05-26 | タレンゲン インターナショナル リミテッドＴａｌｅｎｇｅｎ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｌｉｍｉｔｅｄ | 子宮膣部びらんを予防及び治療するための方法 |
| TW201822790A (zh) | 2016-12-15 | 2018-07-01 | 大陸商深圳瑞健生命科學研究院有限公司 | 一種預防和治療皮膚纖維化的方法 |
| CN110167583A (zh) * | 2016-12-15 | 2019-08-23 | 泰伦基国际有限公司 | 一种治疗冠状动脉粥样硬化及其并发症的方法 |
| CN110114081A (zh) * | 2016-12-15 | 2019-08-09 | 泰伦基国际有限公司 | 一种改善心脏病变的方法 |
| JP7168990B2 (ja) | 2016-12-15 | 2022-11-10 | タレンゲン インターナショナル リミテッド | 肥満症を予防および治療するための方法および薬物 |
| DK3643321T3 (da) | 2017-06-19 | 2025-08-18 | Talengen Int Ltd | Plasminogen til anvendelse i behandling af parkinsons og alzheimers sygdom |
| CN113597313A (zh) * | 2019-01-24 | 2021-11-02 | 先觉药业咨询公司 | 用于治疗和预防微血栓形成的纤溶酶原 |
| EP4112069B1 (en) * | 2020-02-26 | 2025-08-06 | Talengen International Limited | Components of the plasminogen activation pathway for use in the treatment of hypertension |
| CA3182911A1 (en) * | 2020-05-11 | 2021-11-18 | Talengen International Limited | Method and drug for treating spinal muscular atrophy |
| TWI875927B (zh) * | 2021-01-19 | 2025-03-11 | 大陸商深圳瑞健生命科學研究院有限公司 | 一種治療神經損傷及其相關病症的方法 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| GB8721951D0 (en) | 1987-09-18 | 1987-10-28 | Thrombosis Research Trust | Organic compounds |
| JP2764264B2 (ja) * | 1987-10-01 | 1998-06-11 | 株式会社ミドリ十字 | 線溶活性増強剤 |
| AU4661493A (en) * | 1992-07-01 | 1994-01-31 | Beth Israel Hospital Boston | Enhancement of thrombolytic therapy with deglycosylated plasminogen |
| DK125693D0 (da) | 1993-11-05 | 1993-11-05 | Novo Nordisk As | |
| DE4411143C2 (de) | 1994-03-30 | 1996-08-01 | Immuno Ag | Thrombosemittel |
| CA2295925A1 (en) | 1997-06-26 | 1999-01-07 | Karolinska Innovations Ab | Kringle domains 1-5 of plasminogen, capable of modulating angiogenesis in vivo |
| ATE349226T1 (de) | 1998-09-29 | 2007-01-15 | Leuven Res & Dev Vzw | Verwendung von verbindungen die alpha2- antiplasmin in vivo reduzieren zur herstellung einer zusammensetzung zur behandlung ischämischer schlaganfälle |
| US6899877B2 (en) | 1999-03-09 | 2005-05-31 | Minu, L.L.C. | Process for generating plasmin in the vitreous of the eye and inducing separation of the posterior hyaloid from the retina |
| WO2001024815A1 (en) | 1999-10-07 | 2001-04-12 | Human Genome Sciences, Inc. | Plasminogen-like polynucleotides, polypeptides, and antibodies |
| US6964764B2 (en) * | 1999-11-13 | 2005-11-15 | Talecris Biotherapeutics, Inc. | Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin |
| US20020159992A1 (en) * | 2000-09-29 | 2002-10-31 | Jack Henkin | Antiangiogenic polypeptides and methods for inhibiting angiogenesis |
| US7067492B2 (en) | 2001-09-06 | 2006-06-27 | Omnio Ab | Method of promoting healing of a tympanic membrane perforation |
| US7202066B2 (en) | 2002-01-29 | 2007-04-10 | Carrington Laboratories, Inc. | Combination of a growth factor and a protease enzyme |
| CN1768138A (zh) | 2002-02-06 | 2006-05-03 | N-酶生物技术有限公司 | 在微生物中生产重组蛋白质的方法 |
| JP4740531B2 (ja) | 2003-09-30 | 2011-08-03 | 雪印乳業株式会社 | 骨吸収抑制剤 |
| US20050250694A1 (en) | 2003-10-10 | 2005-11-10 | Ma Jian-Xing | Compounds useful in inhibiting vascular leakage, inflammation and fibrosis and methods of making and using same |
| US20060257391A1 (en) | 2005-05-11 | 2006-11-16 | Bausch & Lomb Incorporated | Non-surgical method for preventing or reducing the rate of the progression of non-proliferative diabetic retinopathy and the treatment of other ocular conditions |
| CN101002888A (zh) | 2006-01-16 | 2007-07-25 | 陈维森 | 复方糖尿康 |
| US20070196350A1 (en) | 2006-02-22 | 2007-08-23 | Bartels Stephen P | Compositions and Methods for Effecting Controlled Posterior Vitreous Detachment |
| DK2056864T3 (da) | 2006-08-28 | 2014-03-10 | Omnio Healer Ab | Kandidater mod infektion |
| WO2008027000A2 (en) | 2006-08-28 | 2008-03-06 | Omnio Healer Ab | Novel drug target of preventing and treating periodontal disease, improving healing of periodontal wounds and promoting oral health |
| BRPI0816560A2 (pt) | 2007-10-23 | 2015-09-01 | Inst Med Molecular Design Inc | Método de inibição de produção de pai-1 método para prevenção ou melhora de uma doença causada por uma super-produção de pai-1" |
| CA2707266C (en) | 2007-11-29 | 2013-12-31 | Talecris Biotherapeutics, Inc. | Recombinantly modified plasmin |
| US20090208448A1 (en) | 2008-02-15 | 2009-08-20 | Solomon Keith R | Inhibition of angiogenesis |
| WO2010125148A2 (en) * | 2009-04-30 | 2010-11-04 | Catherine Blondel | Methods for treating ocular conditions |
| WO2011004011A1 (en) | 2009-07-10 | 2011-01-13 | Thrombogenics Nv | Variants of plasminogen and plasmin |
| CN102121023B (zh) | 2010-12-22 | 2012-07-04 | 中山大学 | 突变型人纤溶酶原kringle5及其制备方法及应用 |
| JP6085568B2 (ja) | 2011-01-05 | 2017-02-22 | スロンボジェニックス・ナムローゼ・フェンノートシャップＴｈｒｏｍｂｏＧｅｎｉｃｓ ＮＶ | プラスミノーゲンおよびプラスミンの変異体 |
| CN102154253A (zh) | 2011-01-06 | 2011-08-17 | 郑州大学 | 具有抑制血小板凝集功能的微小纤溶酶原突变体及其制备方法和用途 |
| CA2844644A1 (en) | 2011-08-12 | 2013-02-21 | Thrombogenics N.V. | Plasminogen and plasmin variants |
| EP2914575B1 (en) | 2012-10-31 | 2020-10-14 | The Regents Of The University Of Michigan | Plasminogen activator-1 inhibitors and methods of use thereof |
| TW201722994A (zh) | 2013-08-13 | 2017-07-01 | 賽諾菲公司 | 胞漿素原活化素抑制劑-１（ｐａｉ-１）之抗體及其用途 |
| KR20160035077A (ko) | 2013-08-13 | 2016-03-30 | 사노피 | 플라스미노겐 활성인자 저해제-1(pai-1)에 대한 항체 및 그의 용도 |
| CN104789544B (zh) | 2014-01-16 | 2019-11-26 | 中国科学院福建物质结构研究所 | 重组pai-1抑制剂、包含其的组合物及其用于治疗和检测用途 |
| PT3233111T (pt) | 2014-12-19 | 2024-10-10 | Kedrion Biopharma Inc | Composição farmacêutica que compreende éniplasminogénio e seus usos |
| TWI801331B (zh) * | 2015-11-03 | 2023-05-11 | 美商波麥堤克生物治療股份有限公司 | 纖維蛋白溶酶原缺乏症之纖維蛋白溶酶原替代療法 |
| CN108463240A (zh) | 2015-12-18 | 2018-08-28 | 泰伦基国际有限公司 | 一种预防或治疗糖尿病性视网膜病变的方法 |
| TWI653982B (zh) | 2015-12-18 | 2019-03-21 | 大陸商深圳瑞健生命科學研究院有限公司 | Method for preventing or treating acute and chronic thrombosis |
| JP7175270B2 (ja) | 2016-12-15 | 2022-11-18 | タレンゲン インターナショナル リミテッド | グルカゴン、インスリンを正常なバランスに戻らせる方法 |
| CN110167583A (zh) | 2016-12-15 | 2019-08-23 | 泰伦基国际有限公司 | 一种治疗冠状动脉粥样硬化及其并发症的方法 |
-
2016
- 2016-12-16 ES ES16874928T patent/ES2961967T3/es active Active
- 2016-12-16 US US16/063,569 patent/US11338022B2/en active Active
- 2016-12-16 CN CN201680073583.8A patent/CN108778320A/zh active Pending
- 2016-12-16 WO PCT/CN2016/110453 patent/WO2017101871A1/zh not_active Ceased
- 2016-12-16 DK DK16874928.1T patent/DK3391902T5/da active
- 2016-12-16 EP EP16874928.1A patent/EP3391902B1/en active Active
- 2016-12-16 TW TW105141900A patent/TWI624268B/zh active
- 2016-12-16 JP JP2018550638A patent/JP6783870B2/ja active Active
-
2020
- 2020-10-22 JP JP2020177351A patent/JP2021020933A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3391902B1 (en) | 2023-10-18 |
| JP2019501218A (ja) | 2019-01-17 |
| JP2021020933A (ja) | 2021-02-18 |
| CN108778320A (zh) | 2018-11-09 |
| TWI624268B (zh) | 2018-05-21 |
| ES2961967T3 (es) | 2024-03-14 |
| US20190083586A1 (en) | 2019-03-21 |
| DK3391902T5 (da) | 2024-09-23 |
| EP3391902A1 (en) | 2018-10-24 |
| EP3391902A4 (en) | 2019-06-12 |
| CA3008186A1 (en) | 2017-06-22 |
| WO2017101871A1 (zh) | 2017-06-22 |
| US11338022B2 (en) | 2022-05-24 |
| JP6783870B2 (ja) | 2020-11-11 |
| TW201722467A (zh) | 2017-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3395354T3 (da) | Plasminogen til anvendelse i behandling af diabetisk nefropati | |
| DK3119397T3 (da) | Heterocykliske forbindelser til anvendelse i behandling af PI3K-gamma-medierede lidelser | |
| DK3882250T3 (da) | Tetrahydropyranyl-amino-pyrrolopyrimidinon til anvendelse i behandling af btk-medierede forstyrrelser | |
| DK3391902T5 (da) | Plasminogen til anvendelse i behandlingen af diabetisk angiokardiopati | |
| DK3191144T3 (da) | Medicinsk forbinding | |
| DK3197472T3 (da) | Rekombinante phe-frie proteiner til anvendelse i behandlingen af phenylketonuri | |
| DK3481846T3 (da) | 11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande | |
| DK3307296T3 (da) | Timp2 til anvendelse til behandling af aldringsassocierede tilstande | |
| DK3778595T3 (da) | Pancreatitisbehandling | |
| DK3240612T3 (da) | Fremgangsmåder til behandling af nethindesygdomme | |
| DK3362066T3 (da) | Kombinationsterapi til behandling af maligniteter | |
| DK3395353T5 (da) | Plasminogen til anvendelse til behandling eller forebyggelse af diabetes-mellitus-nerveskade | |
| DK3242947T3 (da) | Genterapi og elektroporese til behandling af maligniteter | |
| DK3524255T3 (da) | Sammensætning til behandling af acne | |
| HUE050944T2 (hu) | Kezelési eljárás tradipitant alkalmazásával | |
| DK3456330T3 (da) | Cortexolon-17alpha-valerat til anvendelse ved behandling af tumorer | |
| DK3374497T3 (da) | Modificerede makrofager til anvendelse i behandlingen af kræft | |
| DK3302519T3 (da) | Ornithodoros-moubata-komplement-inhibitor til anvendelse i behandlingen af akut graft-versus-host-sygdom | |
| DK3373874T3 (da) | Medicinsk forbinding | |
| DK3710000T3 (da) | Tradipitant til anvendelse til behandling af gastroparese | |
| DK2994157T3 (da) | Tafa4-forbindelser og anvendelser deraf til behandling af smerte | |
| DK3204038T3 (da) | Sammensætninger omfattende amylase til anvendelse i behandlingen af pruritus | |
| DK3164123T3 (da) | Hidtil ukendte anvendelser af benzylidenguanidinderivater til behandling af proteopatier | |
| DK3149049T3 (da) | Il-22 til anvendelse til behandling af stofskiftesygdomme | |
| DK3236960T3 (da) | Fluralaner til anvendelse i behandling af demodicose |